S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results

U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.

U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.

The Dow traded up 0.27% to 33,689.58 while the NASDAQ rose 0.92% to 11,059.06. The S&P 500 also rose, gaining, 0.54% to 3,955.30.

Also check this: Why These Lululemon Analysts Have Boosted Their Price Targets Ahead Of Earnings

Leading and Lagging Sectors

Information technology shares rose by 1.2% on Thursday. Meanwhile, top gainers in the WULF), up 23%.

In trading on Thursday, communication services shares fell by 0.3%.

Top Headline

 

Ciena Corporation (NYSE:CIEN) reported better-than-expected Q4 sales results.

Ciena reported a fourth-quarter FY22 revenue decline of 6.8% year-on-year to $971 million, beating the consensus of $849.9 million. Non-GAAP EPS of $0.61 also surpassed estimates.

 

Equities Trading UP

 

  • Pharvaris N.V. (NASDAQ:PHVS) shares shot up 168% to $7.00 after the company reported top-line Phase 2 data from the RAPIDe-1 study of PHVS416 for the on-demand treatment of HAE attacks. The primary endpoint and all secondary endpoints were met.
  • Shares of Hello Group Inc. (NASDAQ:MOMO) got a boost, shooting 31% to $6.86 after the company reported better-than-expected Q3 results.
  • Rent the Runway, Inc. (NASDAQ:RENT) shares were also up, gaining 70% to $2.3086 after the company reported better-than-expected Q3 sales results. The company also issued Q4 sales guidance above analyst estimates and raised its FY22 sales guidance above estimates.

 

Equities Trading DOWN

  • Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shares tumbled 70% to $1.1350 after the company announced topline primary Week 48 data from its Phase 3 D-LIVR study of lonafarnib in two regimens in patients with chronic Hepatitis Delta Virus (HDV).
  • Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) were down 48% to $2.15 after the company said the RELIANCE trial for REL-1017 did not meet the primary endpoint.
  • Design Therapeutics, Inc. (NASDAQ:DSGN) was down, falling 44% to $7.07 after the company reported data from its single-ascending dose trial of DT-216 for the treatment of Friedreich ataxia and portfolio progress.

Also check out: Robinhood, NetApp And These 2 Other Stocks Insiders Are Selling

Commodities

In commodity news, oil traded up 0.5% to $72.39 while gold traded up 0.1% at $1,800.40.

Silver traded up 1.4% to $23.235 on Thursday while copper rose 0.4% to $3.8770.

 

Euro zone

European shares closed mostly lower today. The eurozone’s STOXX 600 fell 0.17%, London’s FTSE 100 fell 0.23% while Spain’s IBEX 35 Index fell 0.79%. The German DAX gained 0.02%, French CAC 40 fell 0.20% and Italy’s FTSE MIB Index fell 0.14%.

 

Asia Pacific Markets

Asian markets closed mixed on Thursday, with the Japan’s Nikkei dropping 0.40% and Hong Kong’s Hang Seng Index jumping 3.38%. China’s Shanghai Composite Index fell 0.07%.

The gauge for Japan's service sector sentiment fell by 1.8 points from the previous month to 48.1 in November, while value of loans in Japan climbed 2.7% year-over-year in November. Japan recorded a deficit of JPY 64.1 billion in October, while the country’s economy contracted an annualized 0.8% during the third quarter.

 

Economics

US initial jobless claims rose by 4,000 to 230,000 in the week ending December 3, matching market estimates.

US natural-gas supplies dropped 21 billion cubic feet last week, the EIA said.

 

Check out this: CBOE Volatility Index Settles At Highest Level Since November 18

COVID-19 Update

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 101,104,270 cases with around 1,108,810 deaths. India confirmed a total of at least 44,675,280 cases and 530,640 deaths, while France reported over 38,259,830 COVID-19 cases with 159,450 deaths. In total, there were at least 651,761,810 cases of COVID-19 worldwide with more than 6,652,430 deaths.

Total
0
Shares
Related Posts